Table 2.

Association between aspirin and NSAID dose and duration of use and adenomatous and hyperplastic polyp risk, the TCPS

Polyp types
AdenomatousHyperplastic
ExposuresControlnORa(95% CI)nORa(95% CI)
NSAID use
Never1,6547481.002381.00
Baby aspirin only7013330.79 (0.66–0.93)920.74 (0.56–0.97)
Regular aspirin only3521770.73 (0.58–0.90)630.90 (0.65–1.25)
Nonaspirin NSAIDs only3431250.67 (0.53–0.86)490.73 (0.51–1.04)
COX-2 inhibitor only77210.61 (0.36–1.02)110.98 (0.49–1.93)
Any combination of NSAIDS3041250.60 (0.47–0.76)460.69 (0.48–1.00)
Baby aspirin only, doses/wk
Never1,6547481.002381.00
<753271.03 (0.62–1.71)60.75 (0.31–1.84)
≥76483060.77 (0.64–0.92)860.74 (0.56–0.99)
Ptrend0.010.10
Baby aspirin only, duration (y)
Never1,6547481.002381.00
<53411500.76 (0.61–0.96)390.65 (0.45–0.95)
≥53601830.81 (0.65–1.01)530.85 (0.60–1.21)
Ptrend0.020.07
Regular aspirin only, doses/wk
Never1,6547481.002381.00
<758200.61 (0.36–1.06)111.13 (0.57–2.25)
72291240.75 (0.58–0.97)340.71 (0.46–1.08)
>765330.76 (0.48–1.20)181.30 (0.73–2.32)
Ptrend0.040.22
Regular aspirin only, duration (y)
Never1,6547481.002381.00
<5117480.61 (0.42–0.89)200.87 (0.51–1.47)
≥52351290.78 (0.60–1.00)430.89 (0.61–1.31)
Ptrend0.010.81
Single agent nonaspirin NSAID, doses/wk
None1,6547481.002381.00
<781270.81 (0.51–1.29)131.00 (0.53–1.88)
7124450.72 (0.50–1.04)210.94 (0.56–1.56)
>7215740.59 (0.43–0.80)260.60 (0.38–0.95)
Ptrend0.0020.13
Single agent nonaspirin NSAID, duration (y)
Never1,6547481.002381.00
<5176580.61 (0.44–0.85)170.49 (0.28–0.83)
≥5244880.71 (0.53–0.93)430.97 (0.67–1.41)
Ptrend0.0010.03
Any combination of NSAID, doses/wk
None1,6547481.002381.00
<738210.92 (0.52–1.64)40.55 (0.19–1.63)
785440.80 (0.53–1.19)130.76 (0.40–1.44)
>7181600.45 (0.32–0.62)290.67 (0.42–1.05)
Ptrend<0.00010.26
Any combination of NSAIDs, duration (y)
Never1,6547481.002381.00
<557220.56 (0.33–0.95)90.63 (0.30–1.35)
≥52471030.60 (0.46–0.79)370.71 (0.48–1.06)
Ptrend0.00020.15
  • aAdjusted for age, gender, race, family history, education level, BMI, energy intake, smoking status, alcohol use, physical activity, use of hormone replacement therapy, indication for colonoscopy, study site, and year of study enrollment.